Altogether, these preclinical results have led to a Phase I trial using a combined PD-L1-, PD-L2-, and VISTA-antagonist (CA-170) in lymphoma, and another Phase I trial using an anti-VISTA antibody in patients with advanced solid tumors [28,29,30,31,32,33,34]. The gene discussed is VSIR; the disease is lymphoma.